Acutus Medical Reports Third Quarter 2023 Financial Results

Rhea-AI Summary

Acutus Medical, Inc. (Nasdaq: AFIB) reported third quarter 2023 revenue of $5.2 million, a 44% year-over-year growth, driven by strong distribution revenue from sales of left-heart access products to Medtronic. The company also achieved significant reductions in operating expenses and cash burn, and announced a strategic realignment of resources and corporate restructuring to optimize financial position and maximize free cash flow.

CARLSBAD, Calif., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Acutus Medical, Inc. (“Acutus” or the “Company”) (Nasdaq: AFIB) today reported results for the third quarter of 2023.

Recent Highlights:

• Third quarter revenue of $5.2 million grew 44% year-over-year, led by strong growth in distribution revenue from sales of left-heart access products to Medtronic
• Registered significant year-over-year reductions in both GAAP and non-GAAP operating expenses and cash burn, resulting from disciplined focus on expense management
• Announced strategic realignment of resources and corporate restructuring with the objective of optimizing financial position and maximizing free cash flow
  

Third Quarter 2023 Financial Results
Revenue was $5.2 million for the third quarter of 2023, an increase of 44% compared to $3.6 million for the third quarter of 2022. The improvement over the same quarter last year was primarily driven by sales through the Company’s distribution agreement with Medtronic, higher capital sales, and increases in service, rent and other revenue.

Gross margin on a GAAP basis was negative 64% for the third quarter of 2023 compared to negative 91% for the same quarter last year. Non-GAAP gross margin was negative 60% for the third quarter of 2023 compared to negative 109% for the same quarter last year. The improvement on both a GAAP and non-GAAP basis was driven by higher production volumes primarily related to left-heart access manufacturing, lower manufacturing variances, and reduced manufacturing overhead expenses.

Operating expenses, consisting of research and development and selling, general and administrative expenses on a GAAP basis were $12.2 million for the third quarter of 2023 compared to $15.6 million for the same quarter last year. Non-GAAP operating expenses were $11.1 million for the third quarter of 2023 compared to $15.2 million for the same quarter last year. The decrease in operating expenses on both a GAAP and Non-GAAP basis resulted from reduced discretionary spend, and the reprioritization of certain research and development programs.

Net loss on a GAAP basis was $13.2 million for the third quarter of 2023 and net loss per share was $0.45 on a weighted average basic and diluted outstanding share count of 29.3 million, compared to a net loss of $20.4 million and a net loss per share of $0.72 on a weighted average basic and diluted outstanding share count of 28.4 million for the same quarter last year. Non-GAAP net loss for the third quarter of 2023 was $15.2 million, or $0.52 per share, compared to non-GAAP net loss of $20.0 million, or $0.70 per share, for the third quarter of 2022.

Cash, cash equivalents, marketable securities and restricted cash were $45.5 million as of September 30, 2023.

Outlook
Due to the announced plan to realign resources to support the left-heart access distribution business and exit from the electrophysiology mapping and ablation businesses, the Company will no longer provide financial guidance.

Non-GAAP Financial Measures
This press release includes references to non-GAAP gross margin, non-GAAP operating expenses, non-GAAP net loss and non-GAAP basic and diluted net loss per share, which are non-GAAP financial measures, to provide information that may assist investors in understanding the Company’s financial results and assessing its prospects for future performance. The Company believes these non-GAAP financial measures are important indicators of its operating performance because they exclude items that are primarily non-cash accounting line items unrelated to, and may not be indicative of, the Company’s core operating results. These non-GAAP financial measures, as Acutus calculates them, may not necessarily be comparable to similarly titled measures of other companies and may not be appropriate measures for comparing the performance of other companies relative to the Company. These non-GAAP financial results are not intended to represent and should not be considered to be more meaningful measures than, or alternatives to, measures of operating performance as determined in accordance with GAAP. Non-GAAP net loss is defined as net loss before income taxes, and all non-GAAP figures provided herein adjust for stock-based compensation, amortization of acquisition-related intangibles, employee retention credit, restructuring charges, changes in the fair value of contingent consideration, gain on sale of business, and change in fair value of warrant liability (as applicable). To the extent such non-GAAP financial measures are used in the future, the Company expects to calculate them using a consistent method from period to period. A reconciliation of the most directly comparable GAAP financial measure to the non-GAAP financial measure has been provided under the heading “Reconciliation of GAAP Results to Non-GAAP Results” in the financial statement tables attached to this press release.

About Acutus
Acutus is focused on the production of left-heart access products under its distribution agreement with Medtronic, Inc. Founded in 2011, Acutus is based in Carlsbad, California.

Caution Regarding Forward-Looking Statements
This press release includes statements that may constitute “forward-looking” statements, usually containing the words “believe,” “estimate,” “project,” “expect” or similar expressions. Forward-looking statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, the Company’s ability to continue to manage expenses and cash burn rate at sustainable levels, successful completion of the Company’s restructuring plan, continued acceptance of the Company’s left-heart access products in the marketplace, the effect of global economic conditions on the ability and willingness of Medtronic to purchase the Company’s left-heart access products and the timing of such purchases, competitive factors, changes resulting from healthcare policy in the United States and globally including changes in government reimbursement of procedures, dependence upon third-party vendors and distributors, timing of regulatory approvals, the Company’s ability to maintain its listing on Nasdaq, and other risks discussed in the Company’s periodic and other filings with the Securities and Exchange Commission. By making these forward-looking statements, Acutus undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law.

Investor Contact:
Chad Hollister
Acutus Medical, Inc.
investors@acutus.com

ACUTUS MEDICAL, INC.
Condensed Consolidated Balance Sheets
(in thousands, except per share amounts)
	September 30, 2023				December 31, 2022
	(unaudited)
ASSETS
Current assets:
Cash and cash equivalents	$	24,100			$	25,584
Marketable securities, short-term		14,375				44,863
Restricted cash, short-term		7,015				5,764
Accounts receivable		8,952				21,085
Inventory		15,728				13,327
Employer retention credit receivable		—				4,703
Prepaid expenses and other current assets		2,467				2,541
Total current assets		72,637				117,867
Property and equipment, net		6,611				9,221
Right-of-use asset, net		3,359				3,872
Intangible assets, net		1,433				1,583
Other assets		688				897
Total assets	$	84,728			$	133,440
LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities:
Accounts payable	$	4,754			$	4,721
Accrued liabilities		7,438				9,686
Contingent consideration, short-term		—				1,800
Operating lease liabilities, short-term		707				319
Warrant liability		1,868				3,346
Total current liabilities		14,767				19,872
Operating lease liabilities, long-term		3,462				4,103
Long-term debt		34,761				34,434
Other long-term liabilities		32				12
Total liabilities		53,022				58,421
Commitments and contingencies
Stockholders' equity
Preferred stock, $0.001 par value; 5,000,000 shares authorized as of September 30, 2023 and December 31, 2022; 6,666 shares of the preferred stock, designated as Series A Common Equivalent Preferred Stock, are issued and outstanding as of September 30, 2023 and December 31, 2022		—				—
Common stock, $0.001 par value; 260,000,000 shares authorized as of September 30, 2023 and December 31, 2022; 29,289,934 and 28,554,656 shares issued and outstanding as of September 30, 2023 and December 31, 2022, respectively		29				29
Additional paid-in capital		598,842				594,173
Accumulated deficit		(566,212	)			(518,314	)
Accumulated other comprehensive loss		(953	)			(869	)
Total stockholders' equity		31,706				75,019
Total liabilities and stockholders' equity	$	84,728			$	133,440

ACUTUS MEDICAL, INC.
Condensed Consolidated Statements of Operations and Comprehensive Loss
(in thousands, except per share amounts)
	Three Months Ended September 30,								Nine Months Ended September 30,
		2023				2022				2023				2022
	(unaudited)
Revenue	$	5,238			$	3,644			$	14,696			$	11,401
Cost of products sold		8,595				6,951				23,447				23,589
Gross profit		(3,357	)			(3,307	)			(8,751	)			(12,188	)
Operating expenses (income):
Research and development		4,795				5,946				17,712				21,884
Selling, general and administrative		7,432				9,679				26,280				38,207
Goodwill impairment		—				—				—				12,026
Restructuring		—				1,331				475				2,280
Change in fair value of contingent consideration		—				198				123				1,153
Gain on sale of business		(2,648	)			—				(5,927	)			(43,575	)
Total operating expenses		9,579				17,154				38,663				31,975
Loss from operations		(12,936	)			(20,461	)			(47,414	)			(44,163	)
Other income (expense):
Loss on debt extinguishment		—				—				—				(7,947	)
Change in fair value of warrant liability		636				904				1,478				904
Interest income		547				241				2,223				292
Interest expense		(1,409	)			(1,109	)			(4,110	)			(3,810	)
Total other income (expense), net		(226	)			36				(409	)			(10,561	)
Loss before income taxes		(13,162	)			(20,425	)			(47,823	)			(54,724	)
Income tax expense		75				—				75				—
Net loss	$	(13,237	)		$	(20,425	)		$	(47,898	)		$	(54,724	)
Other comprehensive income (loss):
Unrealized gain on marketable securities		4				39				7				—
Foreign currency translation adjustment		(66	)			(351	)			(91	)			(904	)
Comprehensive loss	$	(13,299	)		$	(20,737	)		$	(47,982	)		$	(55,628	)
Net loss per common share, basic and diluted	$	(0.45	)		$	(0.72	)		$	(1.65	)		$	(1.93	)
Weighted average shares outstanding, basic and diluted		29,262,768				28,359,516				29,024,353				28,273,207

ACUTUS MEDICAL, INC.
Condensed Consolidated Statements of Cash Flows
(in thousands)
	Nine Months Ended September 30,
		2023				2022
	(unaudited)
Cash flows from operating activities
Net loss	$	(47,898	)		$	(54,724	)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation expense		3,498				4,653
AcQMap Systems converted to sales		238				266
Sales-type lease gain		(310	)			(87	)
Amortization of intangible assets		150				370
Non-cash stock-based compensation expense		4,915				7,497
(Accretion of discounts) amortization of premiums on marketable securities, net		(1,318	)			237
Amortization of debt issuance cost		325				741
Amortization of operating lease right-of-use assets		513				480
Loss on debt extinguishment		—				7,947
Goodwill impairment		—				12,026
Gain on sale of business, net		(5,927	)			(43,575	)
Direct costs paid related to sale of business		—				(2,917	)
Change in fair value of warrant liability		(1,478	)			(904	)
Loss on disposal of property and equipment		268				—
Change in fair value of contingent consideration		123				1,153
Changes in operating assets and liabilities:
Accounts receivable		1,244				420
Inventory		(2,401	)			1,812
Employer retention credit receivable		4,703				—
Prepaid expenses and other current assets		420				(4,296	)
Other assets		495				386
Accounts payable		(2	)			(2,929	)
Accrued liabilities		(2,430	)			(179	)
Operating lease liabilities		(253	)			(390	)
Other long-term liabilities		20				(40	)
Net cash used in operating activities		(45,105	)			(72,053	)
Cash flows from investing activities
Proceeds from sale of business		17,000				50,000
Purchases of available-for-sale marketable securities		(38,521	)			(33,235	)
Sales of available-for-sale marketable securities		—				18,599
Maturities of available-for-sale marketable securities		70,250				59,642
Purchases of property and equipment		(1,394	)			(2,473	)
Net cash provided by investing activities		47,335				92,533
Cash flows from financing activities
Repayment of debt		—				(44,550	)
Penalty fees paid for early prepayment of debt		—				(1,063	)
Borrowing under new debt		—				34,825
Payment of debt issuance costs		—				(626	)
Proceeds from the exercise of stock options		4				66
Repurchase of common shares to pay employee withholding taxes		(275	)			(62	)
Proceeds from employee stock purchase plan		25				182
Payment of contingent consideration		(1,923	)			(873	)
Net cash used in financing activities		(2,169	)			(12,101	)
Effect of exchange rate changes on cash, cash equivalents and restricted cash		(294	)			(447	)
Net change in cash, cash equivalents and restricted cash		(233	)			7,932
Cash, cash equivalents and restricted cash, at the beginning of the period		31,348				24,221
Cash, cash equivalents and restricted cash, at the end of the period	$	31,115			$	32,153
Supplemental disclosure of cash flow information:
Cash paid for interest	$	3,731			$	3,101
	Nine Months Ended September 30,
		2023				2022
	(unaudited)
Supplemental disclosure of noncash investing and financing activities:
Accounts receivable from sale of business	$	6,111			$	—
Change in unrealized (gain) loss on marketable securities	$	(7	)		$	—
Change in unpaid purchases of property and equipment	$	35			$	48
Contingent consideration escrow release	$	—			$	380
Net book value on AcQMap system sales-type leases	$	238			$	244
Amount of debt proceeds allocated to warrant liability	$	—			$	3,379

ACUTUS MEDICAL, INC.
Reconciliation of GAAP Results to Non-GAAP Results
(in thousands)
(unaudited)
Three Months Ended September 30, 2023		Cost of Products Sold				Research and Development				Selling, General and Administrative				Loss from Operations				Other Expense, Net				Net Loss				Basic and Diluted EPS
Reported		$	8,595			$	4,795			$	7,432			$	(12,936	)		$	(226	)		$	(13,237	)		$	(0.45	)
Amortization of acquired intangibles			(50	)			—				—				50				—				50				—
Stock-based compensation			(146	)			(317	)			(815	)			1,278				—				1,278				0.04
Change in fair value of warrant liability			—				—				—				—				(636	)			(636	)			(0.02	)
Change in fair value of contingent consideration			—				—				—				—				—				—				0.00
Gain on sale of business			—				—				—				(2,648	)			—				(2,648	)			(0.09	)
Adjusted		$	8,399			$	4,478			$	6,617			$	(14,256	)		$	(862	)		$	(15,193	)		$	(0.52	)
Three Months Ended September 30, 2022		Cost of Products Sold				Research and Development				Selling, General and Administrative				Loss from Operations				Other Income (Expense), Net				Net Loss				Basic and Diluted EPS
Reported		$	6,951			$	5,946			$	9,679			$	(20,461	)		$	36			$	(20,425	)		$	(0.72	)
Amortization of acquired intangibles			(50	)			—				—				50				—				50				—
Stock-based compensation			(93	)			(349	)			(1,442	)			1,884				—				1,884				0.07
Change in fair value of warrant liability			—				—				—				—				(904	)			(904	)			(0.03	)
Change in fair value of contingent consideration			—				—				—				198				—				198				0.01
Restructuring			—				—				—				1,331				—				1,331				0.05
Employee retention credit			813				414				919				(2,146	)			—				(2,146	)			(0.08	)
Adjusted		$	7,621			$	6,011			$	9,156			$	(19,144	)		$	(868	)		$	(20,012	)		$	(0.70	)

ACUTUS MEDICAL, INC.
Key Business Metrics
(unaudited)

Installed Base and Procedure Volumes

The total installed base which includes AcQMap Systems as of September 30, 2023 and 2022 are as follows:

	As of September 30,
	2023		2022
Acutus
U.S.	26		32
Outside the U.S.	56		42
Total Acutus net system placements	82		74

Procedure volumes for the three and nine months ended September 30, 2023 and 2022 are as follows:

	Three Months Ended				Nine Months Ended
	September 30,				September 30,
	2023		2022		2023		2022
Procedure volumes	531		441		1,566		1,389

Revenue

The following table sets forth the Company’s revenue for disposables, systems and service/other for the three and nine months ended September 30, 2023 and 2022 (in thousands):

	Three Months Ended						Nine Months Ended
	September 30,						September 30,
	2023			2022			2023			2022
Disposables	$	4,069		$	2,857		$	11,409		$	9,402
Systems		563			476			1,254			823
Service / other		606			311			2,033			1,176
Total revenue	$	5,238		$	3,644		$	14,696		$	11,401

The following table presents revenue by geographic location for the three and nine months ended September 30, 2023 and 2022 (in thousands):

	Three Months Ended						Nine Months Ended
	September 30,						September 30,
	2023			2022			2023			2022
United States	$	3,347		$	1,925		$	8,720		$	5,985
Outside the United States		1,891			1,719			5,976			5,416
Total revenue	$	5,238		$	3,644		$	14,696		$	11,401

FAQ

What is the ticker symbol for Acutus Medical, Inc.?

The ticker symbol for Acutus Medical, Inc. is AFIB on the Nasdaq.

What were the third quarter 2023 revenue and growth for Acutus Medical, Inc.?

The company reported third quarter 2023 revenue of $5.2 million, representing a 44% year-over-year growth.

What were the key highlights of Acutus Medical, Inc.'s recent report?

The key highlights include significant year-over-year reductions in operating expenses and cash burn, as well as a strategic realignment of resources and corporate restructuring to optimize financial position and maximize free cash flow.

What were the non-GAAP financial measures mentioned in the press release?

The press release references non-GAAP gross margin, non-GAAP operating expenses, non-GAAP net loss, and non-GAAP basic and diluted net loss per share as important indicators of the company's operating performance.

What is the outlook for Acutus Medical, Inc. following the announced plan to realign resources?

Due to the announced plan to realign resources, the company will no longer provide financial guidance.